The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
 
Radhika Bansal
No Relationships to Disclose
 
Mizba Baksh
No Relationships to Disclose
 
Jeremy Todd Larsen
No Relationships to Disclose
 
Matthew Hathcock
No Relationships to Disclose
 
David Dingli
No Relationships to Disclose
 
Keith Stewart
Leadership - Genomics England
Stock and Other Ownership Interests - Bluebird Bio; C4 therapeutics; QURE Healthcare
Honoraria - Amgen; GlaxoSmithKline; Janssen Oncology; Oncopeptides; Sanofi/Aventis
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen Oncology; Tempus
Research Funding - Celgene/Bristol-Myers Squibb; Janssen Oncology
Patents, Royalties, Other Intellectual Property - PikSci Inc.
Other Relationship - Tempus
(OPTIONAL) Uncompensated Relationships - Leukemia and Lymphoma Society; Myeloma Investment Fund
 
Prashant Kapoor
Honoraria - BeiGene; Cellectar; Clinical Care Options; GlaxoSmithKline (Inst); Karyopharm Therapeutics; Pharmacyclics; Sanofi (Inst)
Consulting or Advisory Role - Sanofi (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Janssen; Sanofi
 
Taxiarchis Kourelis
No Relationships to Disclose
 
Suzanne R. Hayman
No Relationships to Disclose
 
Rahma M. Warsame
No Relationships to Disclose
 
Rafael Fonseca
Stock and Other Ownership Interests - Adaptive Biotechnologies; Caris Life Sciences; OncoMyx Therapeutics
Honoraria - Abbvie; Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celgene; Janssen; Juno Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; OncoTracker; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; Oncopeptides; OncoTracker; Pfizer; Pharmacyclics; Regeneron; Sanofi; Takeda
Patents, Royalties, Other Intellectual Property - Dr Fonseca has received a patent for the prognostication of MM based on genetic categorization of the disease.
Travel, Accommodations, Expenses - Abbvie; Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celgene; Janssen; Juno Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; OncoTracker; Sanofi; Takeda
Other Relationship - Adaptive Biotechnologies; Caris Life Sciences
 
Peter Leif Bergsagel
Consulting or Advisory Role - Celgene; GlaxoSmithKline; Isis Pharmaceuticals; Janssen; Janssen; Mundipharma; Novartis; Novartis (I); Pfizer (I)
Patents, Royalties, Other Intellectual Property - Mouse model of multiple myeloma
Travel, Accommodations, Expenses - Celgene
 
Sikander Ailawadhi
Honoraria - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Janssen (Inst)
Consulting or Advisory Role - Beigene; Celgene; GlaxoSmithKline; Oncopeptides; Sanofi; Takeda
Research Funding - Amgen (Inst); BMS (Inst); Cellectar (Inst); Janssen Biotech (Inst); MedImmune (Inst); Pharmacyclics (Inst); Phosplatin Therapeutics (Inst); Xencor (Inst)
 
Shaji Kumar
Honoraria - BeiGene
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Cellectar; Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)